8 Jefferies Group BridgeBio Pharma Trades
The first BridgeBio Pharma trade was made in Q1 2023. Since then Jefferies Group bought shares three more times and sold shares on four occasions. The investor sold all their shares in Q1 2025 and doesn't own any shares in BridgeBio Pharma anymore.
Avg closing price
Price range
Sold -185 Thousand shares
Q1 2025
Avg closing price
$33.67
Price range
$28.12
-
$37.59
New holding (+185 Thousand shares)
Q4 2024
Avg closing price
$25.95
Price range
$22.35
-
$29.50
Sold -61.9 Thousand shares
Q2 2024
Avg closing price
$27.34
Price range
$23.00
-
$31.04
Sold 40.3% shares (-41.8 Thousand shares)
Q1 2024
Avg closing price
$34.01
Price range
$27.35
-
$40.45
Increased shares by 75.3% (+44.6 Thousand shares)
Q4 2023
Avg closing price
$30.03
Price range
$24.02
-
$43.89
Sold 78.3% shares (-213 Thousand shares)
Q3 2023
Avg closing price
$28.38
Price range
$16.89
-
$35.01
Increased shares by 69.8% (+112 Thousand shares)
Q2 2023
Avg closing price
$15.05
Price range
$13.29
-
$18.01
New holding (+160 Thousand shares)
Q1 2023
Avg closing price
$11.66
Price range
$7.17
-
$18.55
News about BridgeBio Pharma Inc and Jefferies Group
BridgeBio Pharma, Inc.; Helsinn Group: BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio''s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types
- The potentially first-in-class inhibitor designed to target glutathione peroxidase 4 (GPX4) has the potential to impact approximately 500,000 cancer patien...
Helsinn Healthcare S.A.: Helsinn Group and BridgeBio Pharma''s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ (infigratinib) for Patients with Cholangiocarcinoma
Helsinn Group and BridgeBio Pharma''s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ (infigratinib) for Patients with Ch...